

# VITEK® REVEAL™

## GRAM-NEGATIVE BC PANEL (GN02-AST)



- ✓ Antimicrobial susceptibility testing (AST) results as early as 3 hours directly from positive blood culture.<sup>1</sup>
- ✓ Wide antimicrobial coverage for gram-negative bloodstream infections, with 108 clinically relevant bug drug combinations.



ANTIMICROBIAL DRUG	MIC CALLING RANGE (µg/ml)	Gram-negative bacteria												
		<i>A. baumannii</i> - <i>calcoaceticus</i> complex	<i>C. freundii</i> complex	<i>C. koseri</i>	<i>E. cloacae</i> complex	<i>E. coli</i>	<i>K. aerogenes</i>	<i>K. oxytoca</i>	<i>K. pneumoniae</i> group	<i>P. mirabilis</i>	<i>P. vulgaris</i>	<i>P. aeruginosa</i>	<i>S. marcescens</i>	
Amoxicillin / Clavulanate	4/2 - 16/8					✓		✓	✓	✓				4
Ampicillin / Sulbactam	2/1 - 64/32					✓		✓		✓				3
Cefepime	0.5 - 32		✓	✓	✓	✓	✓	✓	✓			✓		7
Ceftazidime	0.12 - 32	✓	✓	✓	✓	✓	✓	✓	✓					7
Ceftazidime / Avibactam	0.06/4 - 16/4		✓	✓	✓	✓	✓		✓	✓		✓		8
Ceftolozane / Tazobactam	0.12/4 - 32/4		✓	✓	✓	✓	✓	✓		✓	✓	✓		8
Ceftriaxone	0.25 - 16			✓	✓	✓	✓	✓	✓	✓				6
Ciprofloxacin	0.25 - 2		✓		✓	✓	✓	✓	✓		✓	✓	✓	9
Ertapenem	0.12 - 1					✓			✓	✓	✓			4
Imipenem	0.5 - 8	✓		✓	✓	✓		✓	✓			✓	✓	8
Levofloxacin	0.12 - 4		✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	11
Meropenem	0.5 - 16	✓			✓	✓			✓	✓	✓	✓	✓	8
Meropenem / Vaborbactam	1/8 - 16/8		✓	✓	✓	✓	✓	✓	✓	✓				8
Piperacillin / Tazobactam	2/4 - 64/4			✓		✓			✓		✓			4
Tobramycin	0.5 - 8		✓	✓	✓	✓	✓	✓	✓	✓		✓	✓	10
Trimethoprim / Sulfamethoxazole	2/38 - 4/76					✓	✓		✓					3
<b>TOTAL</b>		<b>3</b>	<b>5</b>	<b>9</b>	<b>11</b>	<b>16</b>	<b>10</b>	<b>11</b>	<b>14</b>	<b>10</b>	<b>6</b>	<b>8</b>	<b>5</b>	<b>108</b>

System reports interpretive categories (e.g., "S") for VITEK REVEAL BC GN02-AST according to FDA Susceptibility Test Interpretative Criteria (STIC).

# NOVEL TECHNOLOGY DETERMINES MIC DIRECTLY FROM POSITIVE BLOOD CULTURE

**OPTIMIZE DIAGNOSTICS. MANAGE SEPSIS.**  
With our fast, integrated sepsis solution.

The panel includes highly sensitive nanoporous sensors. The sensors change color in response to metabolic volatiles produced by microorganisms during growth to quantify antibiotic efficacy.



## SIMPLE PREP IN <3 MINUTES



Dilute



Decant



Inoculate



Cover with  
Sensor Panel



Seal Assay



Run AST Panel

AVERAGE 5.5 - 6 HOURS TIME TO RESULT<sup>1,2</sup>

## PERFORMANCE OVERVIEW<sup>1</sup>

- Meets or exceeds FDA acceptance criteria of  $\geq 90\%$  EA/CA,  $\leq 2\%$  VME,  $\leq 3\%$  ME
- Refer to GN02-AST IFU for performance by antimicrobial/organism group
- Only 7 limitations for the 108 antimicrobial/species reported

### Panel Information

Breakpoint Standards: CLSI / FDA STIC

VITEK REVEAL BC GN02-AST PANEL: 424883

Product availability varies by country. Consult your bioMérieux representative.

### References

1. BMX.1.129899 Clinical Trial Summary Report (proprietary, on file at bioMérieux).
2. Rottman M et al. Clinical evaluation of the VITEK® REVEAL™ (previously branded SPECIFIC REVEAL) Rapid AST System with Gram-negative bacteremia samples in 6 hospitals in France and England. Poster presented at: ECCMID; 2022 May; Lisbon, Portugal.

